261 related articles for article (PubMed ID: 23547054)
1. GSK-3α promotes oncogenic KRAS function in pancreatic cancer via TAK1-TAB stabilization and regulation of noncanonical NF-κB.
Bang D; Wilson W; Ryan M; Yeh JJ; Baldwin AS
Cancer Discov; 2013 Jun; 3(6):690-703. PubMed ID: 23547054
[TBL] [Abstract][Full Text] [Related]
2. A new alpha in line between KRAS and NF-κB activation?
Pak C; Miyamoto S
Cancer Discov; 2013 Jun; 3(6):613-5. PubMed ID: 23749528
[TBL] [Abstract][Full Text] [Related]
3. Maintenance of constitutive IkappaB kinase activity by glycogen synthase kinase-3alpha/beta in pancreatic cancer.
Wilson W; Baldwin AS
Cancer Res; 2008 Oct; 68(19):8156-63. PubMed ID: 18829575
[TBL] [Abstract][Full Text] [Related]
4. Transient activation of NF-kappaB through a TAK1/IKK kinase pathway by TGF-beta1 inhibits AP-1/SMAD signaling and apoptosis: implications in liver tumor formation.
Arsura M; Panta GR; Bilyeu JD; Cavin LG; Sovak MA; Oliver AA; Factor V; Heuchel R; Mercurio F; Thorgeirsson SS; Sonenshein GE
Oncogene; 2003 Jan; 22(3):412-25. PubMed ID: 12545162
[TBL] [Abstract][Full Text] [Related]
5. Glycogen synthase kinase-3 inhibition disrupts nuclear factor-kappaB activity in pancreatic cancer, but fails to sensitize to gemcitabine chemotherapy.
Mamaghani S; Patel S; Hedley DW
BMC Cancer; 2009 Apr; 9():132. PubMed ID: 19405981
[TBL] [Abstract][Full Text] [Related]
6. RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer.
Kang R; Hou W; Zhang Q; Chen R; Lee YJ; Bartlett DL; Lotze MT; Tang D; Zeh HJ
Cell Death Dis; 2014 Oct; 5(10):e1480. PubMed ID: 25341034
[TBL] [Abstract][Full Text] [Related]
7. KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma.
Ling J; Kang Y; Zhao R; Xia Q; Lee DF; Chang Z; Li J; Peng B; Fleming JB; Wang H; Liu J; Lemischka IR; Hung MC; Chiao PJ
Cancer Cell; 2012 Jan; 21(1):105-20. PubMed ID: 22264792
[TBL] [Abstract][Full Text] [Related]
8. Resibufogenin suppresses transforming growth factor-β-activated kinase 1-mediated nuclear factor-κB activity through protein kinase C-dependent inhibition of glycogen synthase kinase 3.
Liu L; Liu Y; Liu X; Zhang N; Mao G; Zeng Q; Yin M; Song D; Deng H
Cancer Sci; 2018 Nov; 109(11):3611-3622. PubMed ID: 30168902
[TBL] [Abstract][Full Text] [Related]
9. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
10. NF-κB as a target for pancreatic cancer therapy.
Carbone C; Melisi D
Expert Opin Ther Targets; 2012 Apr; 16 Suppl 2():S1-10. PubMed ID: 22443181
[TBL] [Abstract][Full Text] [Related]
11. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
Halilovic E; She QB; Ye Q; Pagliarini R; Sellers WR; Solit DB; Rosen N
Cancer Res; 2010 Sep; 70(17):6804-14. PubMed ID: 20699365
[TBL] [Abstract][Full Text] [Related]
12. Mutations of p53 and KRAS activate NF-κB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells.
Yang L; Zhou Y; Li Y; Zhou J; Wu Y; Cui Y; Yang G; Hong Y
Cancer Lett; 2015 Feb; 357(2):520-6. PubMed ID: 25499080
[TBL] [Abstract][Full Text] [Related]
13. LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo.
Zhou J; Zheng B; Ji J; Shen F; Min H; Liu B; Wu J; Zhang S
Tumour Biol; 2015 May; 36(5):3301-8. PubMed ID: 25524577
[TBL] [Abstract][Full Text] [Related]
14. NF-κB activity is downregulated by KRAS knockdown in SW620 cells via the RAS-ERK-IκBα pathway.
Lin G; Tang Z; Ye YB; Chen Q
Oncol Rep; 2012 May; 27(5):1527-34. PubMed ID: 22327383
[TBL] [Abstract][Full Text] [Related]
15. Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth.
Dudgeon C; Peng R; Wang P; Sebastiani A; Yu J; Zhang L
Oncogene; 2012 Nov; 31(46):4848-58. PubMed ID: 22286758
[TBL] [Abstract][Full Text] [Related]
16. Minocycline targets the NF-κB Nexus through suppression of TGF-β1-TAK1-IκB signaling in ovarian cancer.
Ataie-Kachoie P; Badar S; Morris DL; Pourgholami MH
Mol Cancer Res; 2013 Oct; 11(10):1279-91. PubMed ID: 23858099
[TBL] [Abstract][Full Text] [Related]
17. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
[TBL] [Abstract][Full Text] [Related]
18. Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells.
Fitzgerald TL; Lertpiriyapong K; Cocco L; Martelli AM; Libra M; Candido S; Montalto G; Cervello M; Steelman L; Abrams SL; McCubrey JA
Adv Biol Regul; 2015 Sep; 59():65-81. PubMed ID: 26257206
[TBL] [Abstract][Full Text] [Related]
19. Genetic deletion of glycogen synthase kinase-3beta abrogates activation of IkappaBalpha kinase, JNK, Akt, and p44/p42 MAPK but potentiates apoptosis induced by tumor necrosis factor.
Takada Y; Fang X; Jamaluddin MS; Boyd DD; Aggarwal BB
J Biol Chem; 2004 Sep; 279(38):39541-54. PubMed ID: 15252041
[TBL] [Abstract][Full Text] [Related]
20. TAB4 stimulates TAK1-TAB1 phosphorylation and binds polyubiquitin to direct signaling to NF-kappaB.
Prickett TD; Ninomiya-Tsuji J; Broglie P; Muratore-Schroeder TL; Shabanowitz J; Hunt DF; Brautigan DL
J Biol Chem; 2008 Jul; 283(28):19245-54. PubMed ID: 18456659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
